Capital raised by Tempest Therapeutics
2 Form D filings · first filed Mar 2026 · Brisbane, CA
President and CEO
Signatory on Tempest Therapeutics's Form D filings · $6.1M raised across 2
Matthew Angel is on file as President and CEO at Tempest Therapeutics in Brisbane, CA. Tempest Therapeutics has 2 Form D filings on record, $6.1M raised in total. Matthew Angel appears as a signatory on the company's filings.
The lead in vivo CAR-T candidate, pairing Tempest's CD7-targeted mRNA lipid nanoparticle (CD7-tLNP) delivery platform with a dual-targeting CD19/BCMA chimeric antigen receptor.
